News coverage about Cyberonics (NASDAQ:CYBX) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyberonics earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.5735896862347 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
TRADEMARK VIOLATION WARNING: This report was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/11/12/cyberonics-cybx-given-news-impact-score-of-0-01.html.
Cyberonics, Inc is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD).
Receive News & Ratings for Cyberonics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyberonics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.